Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772603 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
NCT00772603 is a Phase 3 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 366 participants.
The verdict
NCT00772603, a Phase 3 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
Study Summary
Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
Interventions
- DRUG Placebo
- DRUG 2400mg SPN-804
- DRUG 1200mg SPN-804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772603
The ClinicalTrials.gov registry entry for NCT00772603 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00772603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772603 about?
NCT00772603 is a clinical study titled "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures". Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
What is the current status of trial NCT00772603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2008-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00772603?
The interventions under investigation include: Placebo (DRUG), 2400mg SPN-804 (DRUG), 1200mg SPN-804 (DRUG).
Who is sponsoring clinical trial NCT00772603?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.